Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.

Guijarro-Muñoz I, Sánchez A, Martínez-Martínez E, García JM, Salas C, Provencio M, Alvarez-Vallina L, Sanz L.

Med Oncol. 2013;30(2):572. doi: 10.1007/s12032-013-0572-1. Epub 2013 Apr 12.

PMID:
23579861
2.

Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.

Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H.

Dis Colon Rectum. 2011 Aug;54(8):1026-35. doi: 10.1097/DCR.0b013e31821c44af.

PMID:
21730794
3.

Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.

Vincenzi B, Zoccoli A, Schiavon G, Iuliani M, Pantano F, Dell'aquila E, Ratta R, Muda AO, Perrone G, Brunelli C, Correale P, Riva E, Russo A, Loupakis F, Falcone A, Santini D, Tonini G.

Eur J Cancer. 2013 Apr;49(6):1501-8. doi: 10.1016/j.ejca.2012.11.014. Epub 2012 Dec 22.

PMID:
23266047
4.

Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.

Bruhn MA, Townsend AR, Khoon Lee C, Shivasami A, Price TJ, Wrin J, Arentz G, Tebbutt NC, Hocking C, Cunningham D, Hardingham JE; BHI in collaboration with AGITG.

Int J Cancer. 2014 Aug 1;135(3):731-41. doi: 10.1002/ijc.28698. Epub 2014 Jan 24.

5.

Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.

Tsai HL, Lin CH, Huang CW, Yang IP, Yeh YS, Hsu WH, Wu JY, Kuo CH, Tseng FY, Wang JY.

Int J Clin Exp Pathol. 2015 Feb 1;8(2):1900-10. eCollection 2015.

6.

Biomarkers for antitumor activity of bevacizumab in gastric cancer models.

Yamashita-Kashima Y, Fujimoto-Ouchi K, Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H, Mori K.

BMC Cancer. 2012 Jan 25;12:37. doi: 10.1186/1471-2407-12-37.

7.

Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.

Pohl M, Werner N, Munding J, Tannapfel A, Graeven U, Nickenig G, Schmiegel W, Reinacher-Schick A.

Z Gastroenterol. 2011 Oct;49(10):1398-406. doi: 10.1055/s-0031-1281752. Epub 2011 Sep 30. Review.

PMID:
21964893
8.

Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.

Pentheroudakis G, Kotoula V, Kouvatseas G, Charalambous E, Dionysopoulos D, Zagouri F, Koutras A, Papazisis K, Pectasides D, Samantas E, Dimopoulos MA, Papandreou CN, Fountzilas G.

Clin Breast Cancer. 2014 Oct;14(5):330-8. doi: 10.1016/j.clbc.2014.02.009. Epub 2014 Mar 1.

PMID:
24703319
9.

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.

Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG, Schmiegel W, Hallek M, Hacker UT.

Br J Cancer. 2010 Oct 26;103(9):1407-14. doi: 10.1038/sj.bjc.6605925. Epub 2010 Oct 5.

10.

Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).

Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R, Ramírez-Márquez M.

Drugs R D. 2011;11(2):101-11. doi: 10.2165/11590440-000000000-00000. Review.

11.

Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma.

Tachibana M, Tonomoto Y, Hyakudomi R, Hyakudomi M, Hattori S, Ueda S, Kinugasa S, Yoshimura H.

Dig Liver Dis. 2007 Aug;39(8):725-32. Epub 2007 Jul 3.

PMID:
17611172
12.

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G.

BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.

13.

Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients.

Tahover E, Uziely B, Salah A, Temper M, Peretz T, Hubert A.

Med Oncol. 2013 Mar;30(1):327. doi: 10.1007/s12032-012-0327-4. Epub 2012 Dec 20.

PMID:
23254964
14.

Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.

Shin SJ, Hwang JW, Ahn JB, Rha SY, Roh JK, Chung HC.

Invest New Drugs. 2013 Feb;31(1):1-13. doi: 10.1007/s10637-012-9817-7. Epub 2012 Apr 27.

PMID:
22539090
15.

The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.

Strimpakos A, Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Andreadou A, Sgouros J, Zizi-Sermpetzoglou A, Kominea A, Televantou D, Razis E, Galani E, Pectasides D, Tejpar S, Syrigos K, Fountzilas G.

Clin Colorectal Cancer. 2013 Dec;12(4):267-274.e2. doi: 10.1016/j.clcc.2013.07.001. Epub 2013 Sep 17.

PMID:
24050852
16.

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.

Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shriki J, Stebbing J, Lenz HJ.

Pharmacogenomics J. 2013 Apr;13(2):173-80. doi: 10.1038/tpj.2011.61. Epub 2012 Jan 10.

17.

Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients.

Scartozzi M, Giampieri R, Maccaroni E, Del Prete M, Faloppi L, Bianconi M, Galizia E, Loretelli C, Belvederesi L, Bittoni A, Cascinu S.

Br J Cancer. 2012 Feb 28;106(5):799-804. doi: 10.1038/bjc.2012.17. Epub 2012 Feb 7.

18.

The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.

Hansen TF, Christensen Rd, Andersen RF, Garm Spindler KL, Johnsson A, Jakobsen A.

Int J Colorectal Dis. 2012 Jun;27(6):715-20. doi: 10.1007/s00384-011-1382-6. Epub 2011 Dec 6.

PMID:
22139032
19.

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.

Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E, Vincenzi B, Santini D, Bencardino K, Ricci V, Manzoni M, Danova M, Tonini G, Magnani M, Falcone A, Graziano F.

BMC Cancer. 2011 Jun 14;11:247. doi: 10.1186/1471-2407-11-247.

20.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk